Network biology in development of monoclonal antibody therapeutics

• In silico methods for the design of monoclonal antibody therapies were reviewed.
• The translational focus of the network biology applications was highlighted.
• Translational perspective of the use of mathematical modeling was addressed for development of antibodies.
• Mathematical modeling in mAb development requires compilation of approaches and data at multiple levels to be successful.

Monoclonal antibodies (mAbs) are large glycoproteins that recognize and remove/neutralize a specific target. Inflammation and inflammatory diseases are often treated with mAb-based therapeutics. Mathematical modeling is widely used in development of mAbs. Bioinformatics and structural modeling is used for humanization of mAbs and PK/PD modeling is extensively used in preclinical and clinical development. The objective of this commentary is to introduce systems biology-based modeling that can accelerate and improve development of mAbs.